Valneva (NASDAQ:VALN) Trading Up 8.6% – What’s Next?
by Doug Wharley · The Cerbat GemShares of Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) traded up 8.6% during mid-day trading on Wednesday . The stock traded as high as $6.73 and last traded at $6.57. 54,807 shares changed hands during trading, a decline of 13% from the average session volume of 63,209 shares. The stock had previously closed at $6.05.
Wall Street Analyst Weigh In
Several research firms recently weighed in on VALN. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. The Goldman Sachs Group cut Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a research note on Wednesday, April 22nd. Finally, Guggenheim set a $11.00 price target on Valneva in a research report on Thursday, April 16th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Valneva has an average rating of “Hold” and an average target price of $11.98.
View Our Latest Report on VALN
Valneva Stock Up 4.4%
The company has a market cap of $599.21 million, a P/E ratio of -3.38 and a beta of 1.72. The company’s 50-day moving average is $6.39 and its two-hundred day moving average is $8.43. The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60.
Valneva (NASDAQ:VALN – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. The business had revenue of $35.77 million during the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. As a group, equities analysts predict that Valneva SE Sponsored ADR will post -1 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Valneva
Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new position in Valneva in the 4th quarter worth about $44,000. Marex Group plc bought a new stake in shares of Valneva in the second quarter worth approximately $64,000. XTX Topco Ltd bought a new stake in shares of Valneva in the fourth quarter worth approximately $94,000. VSM Wealth Advisory LLC raised its holdings in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Valneva during the third quarter valued at approximately $124,000. 11.39% of the stock is owned by hedge funds and other institutional investors.
About Valneva
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.
Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.